US · RXRX · BIOTECHNOLOGY
Recursion Pharmaceuticals, Inc. (RXRX) intrinsic value and stock valuation
$2.45as of 2026-11-21 · Mkt cap 1.66B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Recursion Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values RXRX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from RXRX’s statements →
Recursion Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $43.9M | $39.7M | $10M |
| Operating income | -$-648.13M | -$-479M | -$-350.06M | -$-245.73M | -$-182.78M |
| Net income | -$-644.76M | -$-463.66M | -$-328.07M | -$-239.48M | -$-186.48M |
| EPSd | -$-1.44M | -$-1.69M | -$-1.58M | -$-1.36M | -$-1.1M |
| Operating cash flow | -$-371.81M | -$-359.17M | -$-287.78M | -$-83.52M | -$-158.61M |
| Capital expenditure | -$-6.47M | -$-13.7M | -$-11.96M | -$-37.36M | -$-39.8M |
| Free cash flow | -$-378.28M | -$-372.87M | -$-300.33M | -$-120.88M | -$-198.41M |
| Total assets | $1.47B | $1.45B | $653.7M | $701.3M | $610.4M |
| Total debt | $78M | $108.5M | $50.7M | $51M | $11.5M |
| Net debt | -$-665.33M | -$-485.86M | -$-340.89M | -$-498.91M | -$-273.64M |
| Total equity | $1.13B | $1.03B | $463.4M | $485.8M | $542.9M |
| Cash and short-term investments | $743.3M | $594.4M | $391.6M | $549.9M | $516.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $43.9M | $39.7M | $10M |
| Cost of revenue | $121M | $45.2M | $42.6M | $48.3M | $0.00 |
| Gross profit | -$-46.27M | $13.6M | $1.29M | -$-8.59M | $10M |
| Research and development expenses | $425.3M | $314.4M | $241.2M | $155.7M | $135.3M |
| Selling, general and administrative expenses | $176.6M | $178.2M | $110.8M | $81.6M | $57.7M |
| Other expenses | $0.00 | $0.00 | -$-700K | -$-160K | -$-180K |
| Operating expenses | $601.9M | $492.6M | $351.4M | $237.1M | $192.8M |
| Cost and expenses | $722.8M | $537.8M | $393.9M | $285.4M | $192.8M |
| Interest income | $22.8M | $15.8M | $19.1M | $6.25M | $70K |
| Interest expense | $1.81M | $1.57M | $100K | $60K | $2.95M |
| Depreciation and amortization | $83.7M | $36.5M | $24.4M | $11.8M | $8.4M |
| Ebitda | -$-559.38M | -$-426.72M | -$-307.63M | -$-227.66M | -$-175.12M |
| Operating income | -$-648.13M | -$-479M | -$-350.06M | -$-245.73M | -$-182.78M |
| Total other income/expenses, net | $3.24M | $14.2M | $17.9M | $6.25M | -$-3.7M |
| Income before tax | -$-644.89M | -$-464.79M | -$-332.13M | -$-239.48M | -$-186.48M |
| Income tax expense | -$-140K | -$-1.13M | -$-4.06M | $0.00 | $0.00 |
| Net income | -$-644.76M | -$-463.66M | -$-328.07M | -$-239.48M | -$-186.48M |
| Weighted average shares outstanding | $447.5M | $274.2M | $207.9M | $175.5M | $170.3M |
| Weighted average diluted shares outstanding | $447.5M | $274.2M | $207.9M | $175.5M | $170.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $743.3M | $594.4M | $391.6M | $549.9M | $516.6M |
| Net receivables | $24.7M | $49.2M | $3.09M | $2.75M | $9.09M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $812.9M | $714.3M | $438.1M | $569.8M | $534.7M |
| Property, plant and equipment, net | $169.5M | $233.2M | $120.2M | $121.5M | $64.7M |
| Goodwill and intangible assets | $472.1M | $484.7M | $88.5M | $2.11M | $2.19M |
| Long-term investments | $0.00 | $5.63M | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $661.3M | $734.3M | $215.6M | $131.5M | $75.6M |
| Total assets | $1.47B | $1.45B | $653.7M | $701.3M | $610.4M |
| Accounts payable | $18.1M | $21.6M | $3.95M | $4.59M | $2.82M |
| Short-term debt | $21.8M | $22.2M | $6.16M | $6.05M | $1.51M |
| Deferred revenue | $37.6M | $61.8M | $36.4M | $56.7M | $10M |
| Total current liabilities | $147.7M | $187.5M | $93.2M | $100.3M | $46.7M |
| Long-term debt | $56.2M | $86.3M | $44.5M | $45M | $9.97M |
| Deferred revenue, non-current | $114M | $118.8M | $51.2M | $70.3M | $6.67M |
| Total non-current liabilities | $195.6M | $226.3M | $97.1M | $115.2M | $20.8M |
| Capital lease obligations | $59.3M | $81.1M | $49.5M | $50.4M | $10.8M |
| Total liabilities | $343.3M | $413.8M | $190.3M | $215.5M | $67.4M |
| Common stock | $10K | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-2.08B | -$-1.43B | -$-967.62M | -$-639.56M | -$-400.08M |
| Accumulated other comprehensive income (loss) | $36.7M | -$-7.64M | $0.00 | $0.00 | -$-130K |
| Total equity | $1.13B | $1.03B | $463.4M | $485.8M | $542.9M |
| Total investments | $0.00 | $5.63M | $0.00 | $0.00 | $231.5M |
| Total debt | $78M | $108.5M | $50.7M | $51M | $11.5M |
| Net debt | -$-665.33M | -$-485.86M | -$-340.89M | -$-498.91M | -$-273.64M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-644.76M | -$-463.66M | -$-328.07M | -$-239.48M | -$-186.48M |
| Depreciation and amortization | $83.7M | $36.5M | $24.4M | $11.8M | $8.4M |
| Stock-based compensation | $111.2M | $81.7M | $53.5M | $27.9M | $14.8M |
| Change in working capital | $13.7M | -$-38M | -$-44.26M | $104.9M | -$-310K |
| Accounts receivable | $32.9M | -$-6.07M | -$-7.76M | -$0.00 | $110K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $7.83M |
| Accounts payable | -$-2.62M | $6.43M | -$-990K | $1.77M | $1.75M |
| Net cash provided by operating activities | -$-371.81M | -$-359.17M | -$-287.78M | -$-83.52M | -$-158.61M |
| Investments in property, plant and equipment | -$-6.47M | -$-13.7M | -$-11.96M | -$-37.06M | -$-39.8M |
| Acquisitions, net | $0.00 | $277.1M | $1.84M | $0.00 | $232M |
| Net cash used for investing activities | -$-16.87M | $260.1M | -$-10.23M | $193.3M | -$-271.74M |
| Common stock issued | $533M | $300.4M | $128.1M | $143.7M | $462.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $521.5M | $304.1M | $140.1M | $154.3M | $458.5M |
| Net change in cash | $150.9M | $201.6M | -$-157.69M | $263.8M | $28.2M |
| Cash at end of period | $753.9M | $603M | $401.4M | $559.1M | $295.4M |
| Operating cash flow | -$-371.81M | -$-359.17M | -$-287.78M | -$-83.52M | -$-158.61M |
| Capital expenditure | -$-6.47M | -$-13.7M | -$-11.96M | -$-37.36M | -$-39.8M |
| Free cash flow | -$-378.28M | -$-372.87M | -$-300.33M | -$-120.88M | -$-198.41M |
Line items
Line items
Line items
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
- CEO
- Najat Khan
- Employees
- 600
- Beta
- 0.99
Explore
Frequently asked questions
What is the intrinsic value of Recursion Pharmaceuticals, Inc. (RXRX)?
Recursion Pharmaceuticals, Inc. (RXRX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is RXRX undervalued?
RXRX trades at a price of $2.45 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.